Wall Street analysts expect Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) to post ($1.09) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Deciphera Pharmaceuticals’ earnings. The highest EPS estimate is ($1.03) and the lowest is ($1.19). Deciphera Pharmaceuticals posted earnings of ($0.65) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 67.7%. The firm is scheduled to issue its next earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that Deciphera Pharmaceuticals will report full year earnings of ($4.57) per share for the current fiscal year, with EPS estimates ranging from ($5.13) to ($4.27). For the next financial year, analysts expect that the firm will post earnings of ($4.14) per share, with EPS estimates ranging from ($5.08) to ($2.46). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Deciphera Pharmaceuticals.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($1.25) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.41).
In other news, CFO Thomas Patrick Kelly sold 1,473 shares of the company’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $25.06, for a total value of $36,913.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 17,073 shares of company stock valued at $399,388 over the last quarter. Company insiders own 7.02% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Orbimed Advisors LLC lifted its stake in shares of Deciphera Pharmaceuticals by 25.0% in the 4th quarter. Orbimed Advisors LLC now owns 2,442,200 shares of the company’s stock valued at $51,262,000 after acquiring an additional 488,700 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Deciphera Pharmaceuticals by 1,405.1% in the 4th quarter. Millennium Management LLC now owns 1,246,640 shares of the company’s stock valued at $26,167,000 after acquiring an additional 1,163,815 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Deciphera Pharmaceuticals by 4.0% in the 1st quarter. BlackRock Inc. now owns 1,219,974 shares of the company’s stock valued at $28,316,000 after acquiring an additional 46,729 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Deciphera Pharmaceuticals by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 675,517 shares of the company’s stock valued at $26,156,000 after acquiring an additional 14,081 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC lifted its stake in shares of Deciphera Pharmaceuticals by 10.7% in the 1st quarter. ArrowMark Colorado Holdings LLC now owns 393,932 shares of the company’s stock valued at $9,143,000 after acquiring an additional 37,975 shares during the last quarter. Hedge funds and other institutional investors own 58.89% of the company’s stock.
Shares of DCPH opened at $23.16 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.55 and a current ratio of 9.55. Deciphera Pharmaceuticals has a 1 year low of $18.55 and a 1 year high of $45.61. The firm has a market capitalization of $882.19 million, a price-to-earnings ratio of -8.21 and a beta of 2.67.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Featured Story: What does a market perform rating mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.